Release Date: May 1, 2024
Expiration Date: May 1, 2025
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in newly diagnosed multiple myeloma (NDMM). In this educational program, these experts review the latest data on novel treatments for NDMM, discuss their approach to creating individualized treatment plans, and show what these insights mean for your practice.
This educational activity is an archive of the live virtual symposium held on April 19, 2024.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners/physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of MM.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate safety and effectiveness data from trials exploring novel combination therapies to guide treatment
- Decisions for individuals with NDMM based on patient- and disease-specific considerations
- Customize care for patients with NDMM by considering supportive measures and addressing treatment-related adverse events associated with novel combination approaches
- Investigate the benefits and obstacles associated with shared decision-making with patients with NDMM
Thierry Facon, MD
Professor of Hematology
Lille University Hospital
Lille, France
Disclosures: Thierry Facon, MD, has no relevant financial relationships with ineligible companies.
Francesca Gay, MD, PhD
Associate Professor
Department of Molecular Biotechnology and Health Sciences
University of Turin
Turin, Italy
Disclosures: Consultant: AbbVie, GSK, Janssen Pharmaceuticals, Pfizer, Roche, Sanofi, Takeda Pharmaceuticals.
Pieter Sonneveld, MD, PhD
President, European Myeloma Network
Department of Hematology
Erasmus MC Cancer Institute
Rotterdam, Netherlands
Disclosures: Grant/Research Support: Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, Karyopharm; Consultant: Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, Karyopharm, Pfizer.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here